Cellanyx

Commercializing a first-in-class machine learning-powered biopsy-on-a-chip platform for precision cancer testing and personalized therapies.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded January 2013
  • Employees 8
  • Incorporation Type LLC
  • Website cellanyx.com

Company Summary

The absence of reliable predictive diagnostic tests has emerged as a major barrier to personalized medicine in cancer. Cellanyx’s phenotypic platform directly assesses the dynamic behavior of live biopsy cells, uniquely quantifying the hallmarks of cancer and cancer aggressiveness such as cell movement and protein dynamics.

Team

  • Ashok Chander
    Chief Executive Officer, Founder

    SB, MIT; PhD, Columbia University

  • Jonathan Varsanik
    VP Engineering

    SB, MIT; PhD, MIT

  • Michael Manak
    VP Research & Development

    PhD, University of Florida; Post Doctoral Fellow, Harvard Medical School

  • Delaney Berger
    VP of Commercialization

    BS, UMN

  • Nikhil Joshi
    Marketing Lead

    BS, University of California, San Diego; MS, Columbia University

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free